New appointment at Transdel Pharmaceuticals
This article was originally published in Scrip
Transdel Pharmaceuticals, a US speciality company developing topically administered products using its proprietary transdermal delivery platform, has named Terry Nida chief business officer. Mr. Nida was most recently an executive consultant for pharmaceutical and biotechnology companies. He has also worked at Urigen Pharmaceuticals, Vivus, Carrington Laboratories, Centocor and Bristol-Myers.